PURPOSE. Cytochrome P450 3A (CYP3A) is an enzyme of paramount importance to drug metabolism. The expression and activity of CYP3A, an enzyme responsible for active androgen clearance, was investigated in the rabbit lacrimal gland. METHODS. Analysis of CYP3A expression and activity was performed on lacrimal gland tissues obtained from naïve untreated and treated New Zealand White rabbits. For 5 days, treated rabbits received daily administration of vehicle or 0.1% or 1.0% dexamethasone, in the lower cul-de-sac of each eye. Changes in mRNA expression were monitored by real-time RT-PCR. Protein expression was confirmed by Western blot. Functional activity was measured by monitoring the metabolism of CYP3A probe substrates-namely, 7-benzyloxyquinoline (BQ) and
C ytochrome P450 enzymes play crucial roles in the metabolism of drugs, as well as the biosynthesis or degradation of endogenous substrates, such as steroids. 1, 2 This superfamily of heme-containing proteins is arranged into families, subfamilies, and isoforms, on the basis of percentage amino acid sequence identity, denoted by an Arabic numeral, followed by a capital letter, followed by an Arabic numeral, respectively. 3 Members of the cytochrome P450 3A (CYP3A) subfamily are arguably the most important enzymes that participate in the oxidative metabolism of drugs. More than 50% of drugs of structurally diverse chemical classes are estimated to be metabolized by CYP3A isoforms. 4 The expression of CYP3A is mediated through the nuclear receptor (NR1I12), termed the pregnane-X-receptor (PXR). [5] [6] [7] CYP3A and P-glycoprotein (P-gp) may act together as a protective mechanism in cells to remove drugs or endogenous chemicals. 8, 9 Detoxification is achieved through CYP3A, which mediates deactivation of substrates, and P-gp, which acts as an integral membrane protein to export substances from inside cells and from membranes to the outside in an adenosine triphosphate (ATP)-dependent manner.
10 CYP3A and P-gp share broad substrate overlap and tissue distribution.
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CYP3A is predominantly expressed in the liver; however, many extrahepatic tissues that are steroid sensitive express this enzyme. Altered CYP3A metabolism impacts androgen-mediated prostate carcinogenesis and the presentation of prostate cancer. 12 Local expression of CYP3A is relevant to steroid hormone action in the brain 13 and in the endometrium of premenopausal women. 14 In rats, testosterone 6␤ hydroxylation, a reaction catalyzed by CYP3A, 15 was measurable in the thymus. 16 Normal lacrimal gland function is modulated by androgens. 17 The tear secretory system is composed of the main lacrimal gland and the accessory glands, which together generate approximately 98% of tear film. 18 Primary lacrimal deficiency is thought to result when the bioavailability of androgens falls below a critical level. 19 In a study in which female rabbits underwent ovariectomy, total serum testosterone decreased and significant regression of the lacrimal gland was observed. 20 As well, examination of lacrimal glands obtained from a female mouse model of Sjögren's syndrome revealed that testosterone therapy suppresses lymphocyte infiltration, improves the functional activity, and increases androgen receptor expression. 21, 22 Thus, information regarding androgen metabolic routes in the lacrimal gland may give important insight into the pathogenesis and assist in the development of therapeutic intervention.
Keratoconjunctivitis sicca, commonly referred to as dry eye, is estimated to affect 10% to 15% of the U.S. population aged 65 Ϯ 10 years. 23, 24 Dry eye is diagnosed most frequently in aging patients, in particular, postmenopausal women. 25 Fur-thermore, postmenopausal women who use hormone replacement therapy, in particular estrogen alone, have a higher prevalence of dry eye syndrome than do postmenopausal women who have never used hormone-replacement therapy. 26 Younger women, with premature ovarian failure which is associated with hypoandrogenemia and hypoestrogenemia, are more likely to exhibit dry eye symptoms than age-matched control subjects. 27 Men who have dry eye tend to be older and thus are more likely to have lower levels of circulating androgens. 19 Together these observations support the notion that dry eye is connected to sex steroid levels.
Oxidative metabolism of androgens to inactive metabolites is a relatively unexplored area in ocular tissues. Although, it was observed that testosterone could undergo oxidative metabolism in the rabbit eye. 28, 29 However, the nature of the metabolites and the enzymes responsible have not been identified. With the arrival of more sensitive technologies, including molecular biology techniques and the characterization of probe substrates for specific enzymes, we now have tools that allow us to better study ocular metabolism.
In this study, we set out to map the drug-metabolism machinery in the rabbit lacrimal gland and to assess its possible role in lacrimal gland physiology. We used testosterone as a tool to probe CYP3A activity. 15 We used dexamethasone, a known CYP3A inducer, 5 and cyclosporine, retinoic acid, and ketoconazole, known substrates and competitive inhibitors of CYP3A, 30 -32 as tools to modulate CYP3A activity. These compounds were chosen primarily due to their common use in the study of CYP3A metabolism in other tissues and secondarily for their respective relevance as either ophthalmic drugs and/or endogenous substrates.
The primary objective of this study was to determine whether CYP3A was expressed and active in the rabbit lacrimal gland and if so, could this activity be modulated. In this study, we confirmed the expression of the isoform CYP3A6 by quantitative RT-PCR and Western blot in the rabbit lacrimal gland and also measured the gene expression of PXR and P-gp in this tissue. We describe the modulation of CYP3A6-mediated metabolism of testosterone in the lacrimal gland in response to dexamethasone ophthalmic treatment and in vitro inhibition by ketoconazole, all-trans retinoic acid and cyclosporine.
MATERIALS AND METHODS

Chemicals and Reagents
Potassium phosphate (monobasic), potassium phosphate (dibasic), sodium citrate (tribasic), glucose-6-phosphate, and nicotinamide dinucleotide diphosphate (NADP)-sodium salt, cyclosporine, all-trans retinoic acid, ketoconazole, 17␤-estradiol, dexamethasone 21-phosphate disodium, and [
3 H]testosterone were purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO); 7-benzyloxyquinoline (BQ) from BD Gentest (Woburn, MA); 2␤-, 6␤-, 7␣-, 15␤-, and 16␤-hydroxytestosterone from Steraloids, Inc. (Newport, RI); and glucose-6-phosphate dehydrogenase from Roche Diagnostics (Indianapolis, IN). Polyclonal antibody raised in rabbit against rat CYP3A1/2 was obtained from Xenotech LLC (Kansas City, KS) and polyclonal antibody raised in rabbit against rat NADPH reductase protein from Stressgen (Victoria, BC, Canada). All other chemicals and reagents were of the highest grade obtainablereagent grade or better-unless otherwise noted.
Animals
The care and use of all animals was in accordance with the guidelines outlined in the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research, in addition to the policies of the Allergan Animal Care and Use Committee. Male New Zealand White rabbits, weighing 3.0 to 3.5 kg (Charles River Laboratories, Inc., Wilmington, MA), were used for all studies described. Rabbits were euthanatized by an injection of an overdose of pentobarbital sodium (85 mg/kg) into the marginal vein of the ear. Lacrimal gland, small intestine, and liver tissues were harvested from four naïve untreated male New Zealand White rabbits. Treated rabbits received 0.9% saline (vehicle control group, n ϭ 4) or 0.1% (n ϭ 6) or 1.0% (n ϭ 6) dexamethasone 21-phosphate disodium salt, four times daily, for 5 days. Each rabbit received a single 50-L drop of the appropriate treatment at the designated time in the lower cul-de-sac of each eye. On the fifth day of treatment, 2 hours after the last dose, the rabbits were killed, and the lacrimal glands were collected for RNA extraction and microsome preparation.
Microsome Preparation
Lacrimal gland and liver tissues collected from naïve untreated rabbits were processed into microsomes by standard differential centrifugation methodology 33 and 1.15% potassium chloride as the homogenization buffer. Small intestine microsomes from naïve untreated rabbits were prepared in a similar manner, except that the homogenization buffer contained 0.1 mM phenylmethylsulfonyl fluoride in 1.15% potassium chloride. Lacrimal gland microsomes prepared from treated rabbits were prepared in a similar manner, except that the homogenization buffer contained 0.1 mM Tris buffer, 0.1 mM EDTA, 0.1 mM phenylmethylsulfonyl fluoride, 20% glycerol, 0.001% aprotinin, and 0.001% leupeptin in 1.15% potassium chloride. Protein concentration was determined spectrophotometrically using a protein assay kit (BioRad; Hercules, CA). Cytochrome P450 content was measured spectrophotometrically using the carbon monoxide difference method.
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Gene Expression Analysis
Total RNA was extracted from rabbit lacrimal gland and liver tissue (TRIzol Reagent; Invitrogen-Gibco, Grand Island, NY) according to the manufacturer's suggested protocol. cDNA was synthesized using a cDNA synthesis kit (iScript; Bio-Rad Laboratories, Hercules, CA). The rabbit mRNA sequences for CYP3A6, P-glycoprotein (P-gp), pregnane-X-receptor (PXR), androgen receptor (AR), and ␤-actin were downloaded from GenBank (http://www.ncbi.nlm.nih.gov/GenBank). A computer program (Beacon Designer 2.0; Premier Biosoft International, Palo Alto, CA) was used to design the primer sequences. The primer sequences and other relevant information are presented in Table 1 . Real-time quantitative RT-PCR was performed in a thermocy- 
Western Blot Analysis
Microsomal proteins (10 g) were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Incubations with primary antibody were for 60 minutes at room temperature. The membranes were incubated for 60 minutes at room temperature with the secondary antibody raised in goat against rabbit, with an alkaline phosphatase label (Bio-Rad) with gentle agitation. After secondary antibody incubation, the proteins were visualized using a chemiluminescent protein detection system (Immun-Star; Bio-Rad).
7-BQ Assay
The dealkylation of 7-BQ was used to monitor CYP3A6 activity. Lacrimal gland, small intestine, and liver microsomes (1 mg/mL) were incubated at 37°C, in 0.2 mL final volume, with 100 M BQ, for 60 minutes. Incubations included the NADPH regeneration system which contained 0.4 mM NADP, 4 mM glucose-6-phosphate, 2 mM MgCl 2 , 0.6 U/mL glucose-6-phosphate dehydrogenase, and 1 mM NAD in 100 mM potassium phosphate buffer. Rabbit liver microsomes were tested as a positive control. Incubations were performed in the absence of an NADPH-regenerating system as a negative control. All incubations were performed in triplicate. The production of the fluorescent BQ metabolite, 7-hydroxyquinoline, was measured using an excitation wavelength of 410 nm and emission wavelength of 530 nm, as detected by a fluorometer (FLUOstar Galaxy; BMG Labtechnologies GmbH, Offenburg, Germany).
[ 3 H]Testosterone In Vitro Metabolism
The microsomal incubation mixture contained 10 M/2 Ci per milliliter [ 3 H]testosterone and 1 mg/mL lacrimal gland microsomal protein in a total incubation volume of 1 mL. Incubations included the NADPHregenerating system in 100 mM potassium phosphate buffer. Incubations were performed at 37°C in a shaking water bath (Precision, Chicago, IL). Incubations were performed in the absence of an NADPH regenerating system as a negative control. All incubations were performed in duplicate. A 500-L aliquot was removed from the microsomal reaction mixture at the 0-and 60-minute time points and transferred to a test tube containing 1500 L ice-cold dichloromethane. The resultant sample (2.0 mL) was centrifuged at 1000 g for 10 minutes. The supernatant was removed and the bottom layer was evaporated to dryness under nitrogen, the dried residue was reconstituted in 150 L of mobile phase (water-methanol-acetonitrile, 65:34:1, vol/vol/vol) and 100 L was injected onto the HPLC system.
Chemical Inhibition Studies
Inhibition experiments using ketoconazole, all-trans retinoic acid (ATRA), and cyclosporine (0 -1000 M) as inhibitors of CYP3A were conducted in a similar manner. Both the inhibitor and [
3 H]testosterone acid were added to lacrimal gland microsomes (1 mg/mL) before addition of cofactors in a total volume of 0.5 mL and incubated for 60 minutes at 37°C. All incubations were performed in duplicate. IC 50 was determined by fitting each inhibition data set to the four-parameter IC 50 equation by nonlinear regression analysis (GraFit, ver. 4.0; Erithacus Software Ltd., London, UK). 
Bioanalysis
Statistical Analysis
Comparisons among the treatment group means were performed by one-way analysis of variance (ANOVA). A Dunnett multiple-comparison test was used to discriminate among the means. P Ͻ 0.05 was considered statistically significant.
RESULTS
Characterization of CYP3A in the Naïve Untreated Rabbit Lacrimal Gland
The carbon monoxide difference spectra method 34 was used to measure cytochrome P450 heme protein content in lacrimal gland and liver microsomes prepared from naïve untreated rabbit tissues. Cytochrome P450 heme protein content in lacrimal gland microsomes was determined to be 44.6 picomoles/mg protein compared with 729 picomoles/mg protein in liver microsomes.
The expression of NADPH-reductase protein in the lacrimal gland was identified by Western blot analysis. A protein band with an estimated molecular mass of 78 kDa was detected in lacrimal gland and liver microsomes (Fig. 1A) . The expected molecular weight of NADPH-reductase protein is 78 kDa. 36 A second band with an estimated molecular mass of 50 kDa was detected in lacrimal gland and liver microsomes. This cross reactivity is probably cytochrome P450 heme protein which has an expected molecular mass of approximately 50 kDa. 37 To evaluate CYP3A6 gene expression in the rabbit lacrimal gland, RT-PCR was performed. In addition, PXR, P-gp, and AR were probed in the rabbit lacrimal gland (Fig. 2) . CYP3A6 was expressed in the lacrimal gland, although expression levels were more than 240-fold lower than the levels detected in the liver, as measured using real-time RT-PCR. Transcript copies of PXR and P-gp were also detected in the rabbit lacrimal gland, and the levels of expression were Ͼ160-fold and Ͼ300-fold lower, respectively, than the levels detected in the liver. We also confirm previous observations that the AR is expressed in the lacrimal gland. 38 The expression of CYP3A6 in the lacrimal gland was confirmed by Western blot analysis. A protein band with an estimated molecular mass of 50 kDa, the expected molecular mass of CYP3A6, 37 was detected in lacrimal gland and liver microsomes (Fig. 1B) .
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7-BQ dealkylation to hydroxyquinoline was measured in microsomes prepared from rabbit lacrimal gland, small intestine, and liver tissues ( Table 2) . BQ is a probe substrate for CYP3A. 39 The rate of 7-BQ dealkylation was measured to be 14 Ϯ 7 picomoles/mg protein per minute in the lacrimal gland compared with 7 Ϯ 3 and 142 Ϯ 18 picomoles/mg protein per minute in the small intestine and liver, respectively. The relative levels of BQ dealkylation in lacrimal gland and small intestine microsomes compared with liver were 10% and 5%, respectively.
Effect of Dexamethasone Topical Administration
Real-time RT-PCR was used to examine quantitative differences in the expression of CYP3A6, PXR, P-gp, and AR after topical treatment with either 0.1% or 1.0% dexamethasone compared with treatment with vehicle control (0.9% saline). A significant increase in CYP3A6 expression (Ͼ2.5-fold, P ϭ 0.01) was observed when comparing the vehicle control to the 1.0% treatment group (Fig. 3 ). Significant induction of P-gp gene expression was observed after 0.1% (Ͼ4-fold) and 1.0% (Ͼ9-fold) dexamethasone. The treatment appeared to suppress AR expression in the rabbit lacrimal gland. In fact, both 0.1% (P ϭ 0.03) and 1.0% (P ϭ 0.02) dexamethasone decreased expression by greater than 50%. Finally, there was no significant quantitative difference in PXR expression after dexamethasone treatment, although, dexamethasone may have induced a tendency to increased expression.
Topical treatment of rabbits with 1.0% dexamethasone resulted in a significant increase in the rate of BQ dealkylation in lacrimal gland microsomes (256 Ϯ 51 picomoles/mg protein per minute) compared with rabbits receiving vehicle treatment (120 Ϯ 9 picomoles/mg protein per minute; Fig. 4A ). Rabbits receiving 0.1% dexamethasone treatment did not result in a significant increase in the rate of BQ dealkylation in lacrimal gland microsomes compared with rabbits that received vehicle treatment.
Similarly, topical treatment of rabbits with 1.0% resulted in a significant increase in the rate of CYP3A6-mediated [ 3 H]testosterone hydroxylation in the lacrimal gland microsomes (41 Ϯ 8 picomoles-equivalents (eq)/mg protein per minute), compared with rabbits receiving vehicle (7 Ϯ 2 picomoleseq/mg protein per minute; Fig. 4B) .
A concomitant increase in [ 3 H]testosterone metabolite formation was observed (Fig. 5) . In particular, increased rates of formation of metabolites specifically mediated by CYP3A such as 15␤-, 6␤-and 2␤-hydroxytestosterone 15 was observed with increasing concentrations of dexamethasone, from 0.1% to 1.0%.
In 0.9% saline-treated rabbits, 6␤-hydroxytestosterone (CYP3A6-mediated formation) and 17␤-estradiol (CYP19 mediated formation) were detected after incubation with [ 3 H]testosterone (Table 3 , Fig. 5C ). After 0.1% dexamethasone treatment, CYP3A6 activity was induced, as indicated by the increased formation of 15␤-, 6␤, and 2␤-hydroxytestosterone (Fig. 5B ). An increase in 17␤-estradiol formation was also observed. After 1.0% dexamethasone treatment, a further induction of CYP3A6 activity was observed, along with an induction of CYP2A activity (7␣-hydroxytestosterone) and CYP2B (16␤-hydroxytestosterone; Fig. 5A ). The rates of formation of specific metabolites are presented in Table 3 .
Effect of Chemical Inhibition on [ 3 H]Testosterone Metabolism in Lacrimal Gland Microsomes
The potential for ketoconazole, all-trans retinoic acid (ATRA), and cyclosporine to inhibit CYP3A6 mediated [ 3 H]testosterone 6␤ hydroxylation was tested in rabbit lacrimal gland microsomes. All three compounds produced concentration-dependent inhibition of [ 3 H]testosterone 6␤ hydroxylation, although, the degree of potency varied. Ketoconazole inhibited CYP3A6-mediated testosterone 6␤ hydroxylation in a concentration-dependent manner with an IC 50 of 3.73 Ϯ 0.83 M (Fig.  6 ). ATRA and cyclosporine were determined to be weaker inhibitors of [ 3 H]testosterone 6␤ hydroxylation in the rabbit lacrimal gland with IC 50 of 9.32 Ϯ 1.05 and 435 Ϯ 98 M, respectively (data not shown).
DISCUSSION
The cytochrome P450 3A (CYP3A) gene subfamily, in particular human CYP3A4, is arguably the most important cytochrome P450 enzyme that participates in oxidative drug metabolism. CYP3A6 is the predominant CYP3A isoform expressed in the rabbit liver 40 and accordingly shares substrate overlap with CYP3A4. 41, 42 Applying this knowledge, we used substrates and antibodies known to react with CYP3A6 and designed our PCR primers against the CYP3A6 sequence. Thus, similar to rabbit liver, CYP3A6 is an expressed and active CYP3A isoform in the rabbit lacrimal gland.
CYP3A Expression and Activity in the Untreated Rabbit Lacrimal Gland
The cytochrome P450 monooxygenase system is composed of the cytochrome P450 heme component and its redox partner NADPH reductase. In this study, both proteins were detected in the rabbit lacrimal gland. The value determined for cytochrome P450 heme content in rabbit liver microsomes was in good agreement with values in the literature. 34 NADPH reductase protein was detected using Western blot. Together, these data establish the expression of the necessary component proteins of the cytochrome P450 monooxygenase system in the naïve rabbit lacrimal gland.
Using BQ dealkylation to probe CYP3A6 activity, we measured approximately 10% the level of enzyme activity in the lacrimal gland as in the liver. For comparison, BQ dealkylation was measured in rabbit small intestine microsomes and determined to be approximately 5% the level of activity measured in liver microsomes. Although the level of expression of cytochrome P450 enzymes in the small intestine is considerably less than in the liver, the importance of CYP3A-mediated metabolism in the gut in first-pass metabolism is well established. Thus, although the relative level of CYP3A6 activity in the lacrimal gland compared with the liver may be low, the low level does not preclude it from being significant to local substrate levels. The expression of CYP3A6 in the rabbit lacrimal gland was confirmed by Western blot (Fig. 1B) .
CYP3A6 gene expression was detected in the rabbit lacrimal gland (Fig. 2) . Furthermore, genes encoding proteins known to work with CYP3A6 and therefore often coexpressed-namely, P-gp and PXR-were also detected. The expression of P-gp in the lacrimal gland identifies another mechanism by which this tissue can decrease the levels of active steroids through efflux transport. Furthermore, the expression of PXR, the nuclear hormone receptor (NR1I12), is notable because this receptor can interact with the CYP3A gene to induce transcription after ligand binding to PXR. 5 Thus, it appears that the lacrimal gland possesses the ability to modulation of CYP3A6 and P-gp 43 activity locally.
Induction of CYP3A after Dexamethasone Treatment
Dexamethasone is a known ligand of PXR 5 and thus can induce the expression of CYP3A and P-gp. Dexamethasone is often used as a tool compound to induce CYP3A activity in tissues where endogenous expression may be low relative to that in the liver. 44, 45 In ophthalmology, dexamethasone is used as a topical anti-inflammatory agent. Together, these characteristics of dexamethasone made it an interesting test compound for our studies.
After our observation that CYP3A6 was indeed expressed in the lacrimal gland, we then hypothesized that topical treatment with dexamethasone may increase local CYP3A6 activity. To test whether CYP3A6 activity could be induced in the lacrimal gland, rabbits were administered topical treatment with 0.9% saline, 0.1% dexamethasone, or 1.0% dexamethasone, and CYP3A6 expression and activity were compared among the different treatment groups.
Real-time RT-PCR analysis revealed a statistically significant increase in CYP3A6 gene expression (Ͼ2.5-fold), after 1.0% dexamethasone treatment. Significant induction of P-gp gene expression was observed after 0.1% dexamethasone treatment (Ͼ4-fold) and 1.0% dexamethasone (Ͼ9-fold). The individual levels of expression of CYP3A6 and P-gp in the rabbits correlated well across treatment groups (R 2 ϭ 0.63, data not shown), supporting the notion that the expression of these two protein is linked through PXR. Dexamethasone treatment suppressed AR expression in the rabbit lacrimal gland, perhaps due to a direct glucocorticoid effect on AR expression. Alternatively, the induction of mechanisms to decrease intracellular levels of active androgens through CYP3A6-mediated metabolism and P-gp efflux may underlie the suppression of AR expression. Androgens can modulate the expression of their own receptors, and AR expression is downregulated in orchiectomized rats. 46 Testosterone administration to these rats resulted 
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in a marked increase in AR expression. Potentially, induction of an androgen clearance pathway in the rabbit lacrimal gland in response to dexamethasone may contribute to the decreased expression of AR due to decreased levels of active androgens. Using the two probe substrates BQ and [ 3 H]testosterone, we determined that the rates of metabolism increased significantly with 1.0% dexamethasone treatment. Furthermore, these activities correlated well, with a correlation factor of 0.69 (data not shown) suggesting that a common enzyme was responsible for the metabolism of these substrates. In fact, when the metabolite profiles obtained after incubation of [ 3 H]testosterone with rabbit lacrimal gland microsomes were examined, indeed the formation of metabolites specifically mediated by CYP3A6 was induced, after topical dexamethasone treatment. In saline-treated rabbits, testosterone metabolites formed specifically via CYP3A6-or CYP19-mediated metabolism were detected. After 0.1% dexamethasone treatment, CYP3A6 activity was induced as indicated by the increased formation of 15␤-, 6␤, and 2␤-hydroxytestosterone. An increase in 17␤-estradiol formation was also observed, indicating induction of CYP19. After 1.0% dexamethasone treatment, a further induction of CYP3A6 activity was observed, along with an induction of CYP2A activity and CYP2B.
CYP3A6, CYP2A, and CYP2B activity produced inactive testosterone metabolites, whereas CYP19 produces the active metabolite, 17␤-estradiol. Furthermore, of the metabolic pathways producing inactive metabolites, only CYP3A6 activity was detected in the saline-treated rabbit lacrimal gland microsomes. Finally, the degree of induction for each specific enzyme was unique to that enzyme. In lacrimal gland microsomes from Overall, our data indicate that dexamethasone induces CYP3A6 expression and activity in the rabbit lacrimal gland after topical administration. However, there is some question as to whether this effect results after dexamethasone absorption into the lacrimal gland through ocular tissues or drug delivery through the systemic circulation. Topical administration of 0.1% dexamethasone disodium phosphate (pro drug), results in low levels of dexamethasone systemic exposure, in rabbits and humans. 47, 48 Although some systemic absorption of dexamethasone was observed after topical administration to rabbits, systemic delivery did not achieve detectable drug levels in the untreated eye, as measured by [ 14 C]radioactivity. 47 Together these data suggest that the effects observed in our study in the lacrimal gland after either 0.1% or 1.0% dexamethasone disodium phosphate topical treatment were probably due in large part to absorption of the drug through ocular tissues.
Inhibition of CYP3A Metabolism by Specific Inhibitors
Finally, the observation that the specific inhibitor ketoconazole 4 and the CYP3A substrates ATRA 31 and cyclosporine 4 can inhibit CYP3A6-mediated testosterone metabolism in lacrimal gland microsomes further supports the expression of CYP3A6 in this tissue. Thus, depending on the endogenous substrates or drugs present, local CYP3A6 metabolism may be altered through inhibition.
Proposed Negative Feedback Loop in the Lacrimal Gland
Based on these preliminary data, a model emerges for the proposed role CYP3A may play in the lacrimal gland control of local androgen levels. Androgens play an important role as steroid gene regulators in many tissues, including ocular tissues, to maintain a healthy state. Tight control of local androgen levels is necessary in these tissues. Thus, expression of drug metabolizing enzymes in ocular tissues may allow for a "fine tuning" mechanism. We propose the negative-feedback model illustrated in Figure 7 . Under normal conditions in the lacrimal gland, testosterone delivered to the cell can act directly on the androgen receptor. Alternatively, depending on the needs of the cell or on the chemical stimulants present, testosterone can be converted to active metabolites that can interact with receptors or feedback to PXR when their levels exceed a critical point. The interaction of ligands with PXR can induce either or both CYP3A and P-gp that can then act to decrease the level of testosterone available in the cell. Dry eye is a multietiological condition associated with androgen deficiency, 19, 49 and, potentially in the diseased state, alterations in these pathways may contribute to abnormal androgen levels.
We also propose that these pathways may offer insight into the adverse effects associated with some ophthalmic drugs as well as potential targets for therapeutic strategy. Ophthalmic drugs could interact with CYP3A, P-gp, or PXR. For example, dexamethasone, an anti-inflammatory agent, could induce the expression of CYP3A, thereby increasing CYP3A-mediated hydroxylation of testosterone to inactive metabolites. This may be an undesirable effect in a patient with dry eye patient who probably already has decreased androgen levels. 19, 25 Alternatively, cyclosporine, an immunosuppressive agent that is approved for the treatment of dry eye, may inhibit CYP3A-mediated hydroxylation of testosterone and thus contribute to maintenance of higher levels of active androgens in a patient with dry eye. Preventing deactivation of testosterone and potentially other active androgens may be beneficial in a patient with dry eye who has decreased androgen levels.
Future studies should examine the effects of local CYP3A metabolism on other ophthalmic drugs. As well, the effect of other modulators of CYP3A activity on androgen levels both in vitro and in vivo should be examined. For example, studying the effects of IL-2, a cytokine released as part of the dry-eye response, on the activity of CYP3A in the lacrimal gland may offer some insight into the physiological role of this enzyme. Incubations were performed at 37°C for 1 hour with 10 M/2 Ci/mL [ 3 H]testosterone and 1 mg/mL lacrimal gland microsomes. Treatments were applied topically four times daily for 5 days. n ϭ 3 rabbits per treatment group. Each incubation was performed at least in duplicate. Data are expressed as picomoles-eq per milligram protein per minute Ϯ SEM. ND, not detected.
Statistical significance when compared to saline control: * P Ͻ 0.01; † P Ͻ 0.05. Finally, the expression and activity of CYP3A should be examined in other ocular tissues affected by dry eye disease, such as the conjunctiva, and in other animal species and humans. Overall, we have demonstrated that CYP3A6 is expressed at the gene and protein levels in the rabbit lacrimal gland. Furthermore, CYP3A6 expression in the lacrimal gland is subject to induction after topical treatment with the commonly prescribed glucocorticoid dexamethasone. Finally, known inhibitors of CYP3A6 can inhibit the metabolism of testosterone in lacrimal gland microsomes. Further study of this local androgen deactivation pathway may provide insight into the mechanisms underlying the disease of dry eye and strategies for therapeutic intervention. 
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